Industry Portals
Biotechnical Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Young & Partners Pharmaceutical Executive Summit 2024: The Impact of Artificial Intelligence on the Creation of Medicines (Pharmaceutical Executive)
Pharmaceutical Executive shares Fred Hassan's and Najat Khan's comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-impact-artificial-intelligence-creation-medicines
Young & Partners 2024 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Michael Christel, Global Editor, MJH Life Sciences; Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion; Doug Long, Vice President, Industry Relations, IQVIA; Peter Marks, M.D., Director, Center of Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners, former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration; Sandy Zweifach, President and CBO, IMIDomics; Peter Young, CEO and President, Young & Partners
Young & Partners 2024 Pharmaceutical Executive Summit: Michael Christel and Sandy Zweifach- The Changing Roles and Relationships of Biotech and Pharma
Michael Christel, Global Editor, MJH Life Sciences; Sandy Zweifach, President and CBO, IMIDomics
Young & Partners 2024 Pharmaceutical Executive Summit: Fred Hassan and Najat Khan- The Impact of Artificial Intelligence on the Creation of Medicines
Fred Hassan, Director, Warburg Pincus; Najat Khan, Chief R&D and Commercial Officer, Recursion
Young & Partners 2024 Pharmaceutical Executive Summit: Doug Long: The Pharmaceutical Market: Trends, Issues and Outlook
Doug Long, Vice President, Industry Relations, IQVIA Holdings Inc.
Young & Partners 2024 Pharmaceutical Executive Summit: Peter Marks and Stephen Spielberg Fireside Chat: Brave New World- Where Are We Heading?
Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration; Dr. Stephen P. Spielberg, MD PhD, Senior Adviser, Young & Partners
Young & Partners 2024 Pharmaceutical Executive Summit: Peter Marks Fireside Chat: Brave New World- Where Are We Heading?
Dr. Peter Marks, Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading? (Pharmaceutical Executive)
Pharmaceutical Executive shares Peter Marks' comments made at the 2024 Young & Partners Pharmaceutical Executive Summit. https://www.pharmexec.com/view/young-partners-pharmaceutical-executive-summit-2024-brave-new-world-where-heading-
Industry Restructuring & Inorganic Growth Through an Era of Chronic Oversupply (World Chemical Forum Speech September 10, 2024)
Young & Partners shares their thoughts and analysis of the global oversupply and uncertainties that have impacted the chemical markets. The presentation addresses the era of chronic oversupply, strategic assessments, M&A market conditions, and Strategic and M&A alternatives.
Chemical Debt Financing Rebounds (ICIS Chemical Business September 6 – September 12, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have rebounded chemical debt financings and the outlook for 2024.
Chemical M&A Retreats Further (ICIS Chemical Business August 31 – September 5, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical M&A and the outlook for 2024.
Chemical Financing Activity Mixed (ICIS Chemical Business May 31 – June 6, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed chemical financing and the outlook for 2024.
Chemical M&A Market Retreats (ICIS Chemical Business May 17 – May 23, 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2024.
Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Young & Partners 2023 Chemical Conference: Speakers Roundtable- What Does the Future Hold?
Peter Young, Young & Partners Mathias Zachert, CEO of Lanxess Kamal Navarthy, President of Reliance Dewey Johnson, SVP Chemical Market Analytics
Young & Partners 2023 Chemical Conference: Dewey Johnson: The Dramatic Energy Industry Changes and Their Impact on Chemicals
Dewey Johnson, SVP Dow Jones, Global Lead Chemical Market Analytics